氯胺酮治疗急性创伤疼痛可减少出院后6个月PTSD和焦虑症状
本研究为前瞻性随机双盲安慰剂对照试验,纳入82例收入一级创伤中心的严重创伤(伤害严重度评分≥15)成人患者(18-64岁),排除妊娠和慢性阿片类药物使用者。患者均使用患者自控镇痛,随机接受可调剂量氯胺酮(起始3 μg/kg/min)或等速0.9%氯化钠溶液。44例(54%)分入氯胺酮组。结果显示氯胺酮组焦虑症状严重程度和PTSD显著较低(p<0.05),3和6个月时再体验症状(PTSD子量表)显著较少(p<0.05)。作者认为急性疼痛治疗中氯胺酮 infusion 可能显著减少创伤后6个月的焦虑和PTSD,此效应可能对再体验症状相关的记忆过程具有特异性。
要点
- 严重创伤(ISS≥15)成人患者(18-64岁)急性疼痛使用可调剂量氯胺酮(起始3 μg/kg/min)或等速0.9%氯化钠溶液,均联合患者自控镇痛。
- 氯胺酮组44/82例(54%),两组人口学、损伤机制/严重度和基线生活质量指标相似。
- 氯胺酮组焦虑症状严重程度显著较低(p<0.05),PTSD显著较低(p<0.05)。
- 3和6个月时氯胺酮组再体验症状(PTSD子量表)显著较少(p<0.05)。
- 作者认为氯胺酮 infusion 可能显著减少严重创伤后6个月的焦虑和PTSD,效应可能对再体验症状相关的记忆过程具有特异性。
适用人群与场景
- 严重创伤成人患者(伤害严重度评分≥15,年龄18-64岁),收入一级创伤中心。
- 排除标准包括妊娠和慢性阿片类药物使用。
- 所有患者均使用患者自控镇痛。
处置流程与药物剂量
- 所有患者使用患者自控镇痛,随机接受可调剂量氯胺酮(起始3 μg/kg/min)或等速0.9%氯化钠溶液。
研究设计与关键结果
- 前瞻性、随机、双盲、安慰剂对照试验,纳入82例严重创伤(ISS≥15)成人患者(18-64岁),收入一级创伤中心,44例(54%)随机分入可调剂量氯胺酮组(起始3 μg/kg/min),其余接受等速0.9%氯化钠溶液。
- 两组人口学、损伤机制/严重度和基线生活质量指标相似。
- 氯胺酮组焦虑症状严重程度显著较低(p<0.05),PTSD显著较低(p<0.05)。
- 氯胺酮组3和6个月时再体验症状(PTSD子量表)显著较少(p<0.05)。
- 生活质量结局使用抑郁焦虑压力量表21、PTSD检查表(DSM-5)、创伤生活质量量表和简明疼痛量表简表在住院时及出院后1、3、6个月测量。
证据类型、等级与局限
- 证据类型:前瞻性、随机、双盲、安慰剂对照试验;证据等级:治疗/护理管理;Level I。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,严重创伤急性疼痛治疗中氯胺酮 infusion 可能显著减少伤后6个月的焦虑和PTSD,此效应可能对再体验症状相关的记忆过程具有特异性。
- 作者建议进一步研究急性氯胺酮给药对PTSD发生相关神经生物学机制的影响,作为改善受伤患者生活质量的潜在新型预防性干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chronic pain, anxiety, depression, and posttraumatic stress disorder (PTSD) are frequently seen after traumatic injury. Ketamine infusions used to treat acute pain may decrease the risk of chronic pain and improve psychological outcomes of injured patients. We hypothesized patients receiving ketamine would have a lower incidence of chronic pain, anxiety, depression, and PTSD.
METHODS: A prospective, randomized, double-blind placebo-controlled trial of severely injured (Injury Severity Score ≥15) adult patients (age, 18-64 years) admitted to a Level 1 trauma center was conducted. Exclusion criteria included pregnancy and chronic opiate use. All patients were prescribed a patient-controlled analgesia and randomized to either adjustable dose ketamine (ADK) starting at 3 μg/kg/min or an equivalent rate of 0.9% normal saline. Quality of life (QoL) outcomes were measured using Depression and Anxiety (Depression Anxiety Stress Scales 21), PTSD (PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-5), Trauma quality of life (TQOL), and pain (Brief Pain Inventory-Short Form) questionnaires at hospitalization, and 1, 3, and 6 months postdischarge. Linear regression analysis evaluated the relationship between groups and baseline pain and mental health outcomes at each follow-up.
RESULTS: Forty-four of 82 patients (54%) were randomized to ADK. Both groups were similar in demographics, injury mechanisms/severity, and baseline QOL measures. Patients in the ketamine group had significantly less anxiety symptom severity ( p < 0.05) and PTSD ( p < 0.05), with significantly less re-experiencing symptoms (subscale of PTSD) at 3 and 6 months ( p < 0.05).
CONCLUSION: Ketamine infusion for acute pain treatment in severe traumatic injury may significantly reduce anxiety and PTSD 6 months after injury. This effect may be specific to the memory processes responsible for re-experiencing symptoms. Further research should explore the effects of acute ketamine administration on the neurobiological mechanisms implicated in the development of PTSD, as this could be a novel preventative intervention to improve QoL for injured patients.
LEVEL OF EVIDENCE/STUDY TYPE: Therapeutic/Care Management; Level I.
参考来源
- Trevino CM, Carver T, Tomas C, et al. Acute traumatic pain treatment with ketamine decreased PTSD and anxiety symptoms 6 months post hospital discharge. J Trauma Acute Care Surg. 2025. PMID: 41417647. doi:10.1097/TA.0000000000004835
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。